Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248229 | 0.83 | PPARA (0.47) | PPARAFTO | |
| SCHEMBL5499841 | 0.75 | PPARA (0.60) | PPARA | |
| SCHEMBL3238540 | 0.75 | PPARG (0.44) | PPARAFTO | |
| SCHEMBL26767281 | 0.64 | CNR2 (0.42) | FTO | |
| SCHEMBL6986828 | 0.64 | FTO (0.38) | FTO | |
| SCHEMBL11850892 | 0.63 | FTO (0.40) | FTO | |
| SCHEMBL26768896 | 0.62 | FTO (0.40) | FTO | |
| SCHEMBL6994893 | 0.60 | FTO (0.38) | FTO | |
| SCHEMBL8164323 | 0.58 | FTO (0.49) | FTO | |
| SCHEMBL3243563 | 0.56 | FTO (0.43) | FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539137-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK SHARP & DOHME (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7297715-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1539137-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060089404-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| EP-1539137-A1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010992-A1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089404-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARA, PPARG, PPARD | PPARA 1/4885FTO 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.